METABOLITES OF 7-(2-(4-(6-FLUORO-3-METHYLBENZO[d]ISOXAZOL-5-YL)PIPERAZIN-1-YL)ETHYL)-2-(PROP-1-YNYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
The present invention provides a compound of the Formula I: Formula I or a pharmaceutically acceptable salt thereof in isolated and purified form wherein R, R1 and R2 are as described herein. The compounds are adenosine A2a receptor antagonists useful in treatment of central nervous system disorders...
Saved in:
Main Authors | , , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
04.10.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention provides a compound of the Formula I: Formula I or a pharmaceutically acceptable salt thereof in isolated and purified form wherein R, R1 and R2 are as described herein. The compounds are adenosine A2a receptor antagonists useful in treatment of central nervous system disorders, such as Parkinsons disease, Extra-Pyramidal Syndrome (EPS) caused by treatment with an antipsychotic agent, restless legs syndrome, Huntington s disease, attention disorders, depression, stroke and psychoses.
La présente invention concerne un composé de formule I : formule I, ou un sel pharmaceutiquement acceptable de celui-ci sous forme isolée et purifiée, formule I dans laquelle R, R1 et R2 sont tels que définis ici. Lesdits composés sont des antagonistes des récepteurs A2a de l'adénosine utilisables dans le cadre du traitement de troubles du système nerveux central, comme la maladie de Parkinson, le syndrome extrapyramidal provoqué par un traitement faisant appel à un agent antipsychotique, le syndrome des jambes sans repos, la chorée de Huntington, les troubles de l'attention, la dépression, l'AVC et les psychoses. |
---|---|
Bibliography: | Application Number: WO2012US30501 |